Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.57 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.52 |
| ▸ | CTSK | P43235 | 3/20 | 0.48 |
| ▸ | CTSL | P07711 | 2/20 | 0.47 |
| ▸ | CTSS | P25774 | 2/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.47 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29014283 | 1.00 | SYK (0.57) | SYKMBOAT4CTSKCTSLCTSS | |
| SCHEMBL22433329 | 0.90 | SYK (0.54) | SYKMBOAT4CTSKCTSLCTSS | |
| SCHEMBL22688555 | 0.88 | SYK (0.54) | SYKMBOAT4CTSKCTSLCTSS | |
| SCHEMBL930559 | 0.87 | MBOAT4 (0.58) | MBOAT4CTSKATMCTRB1LMNA | |
| SCHEMBL22747610 | 0.87 | MBOAT4 (0.58) | MBOAT4CTSKATMCTRB1LMNA | |
| SCHEMBL930561 | 0.87 | MBOAT4 (0.58) | MBOAT4CTSKATMCTRB1LMNA | |
| SCHEMBL7372388 | 0.86 | CTRB1 (0.54) | MBOAT4CTSKATMCTRB1LMNA | |
| SCHEMBL8173806 | 0.86 | CTRB1 (0.54) | MBOAT4CTSKATMCTRB1LMNA | |
| SCHEMBL17280899 | 0.84 | ALDH1A1 (0.53) | MBOAT4CTSKCTSLCTSSCTSB | |
| SCHEMBL22118319 | 0.84 | CTRB1 (0.54) | MBOAT4CTSKATMCTRB1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115867548-B | RIP1K inhibitors | 里格尔药品股份有限公司 | 2025-03-11 | — | — | CN | disclosed |
| US-12043629-B2 | RIP1K inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043629-B2 | RIP1K inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-20230227469-A1 | RIP1K INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230227469-A1 | RIP1K INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2023-07-20 | — | — | US | disclosed |
| CN-115867548-A | RIP1K inhibitors | 里格尔药品股份有限公司 | 2023-03-28 | — | — | CN | disclosed |
| US-11584758-B2 | RIP1K inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| EP-4126864-A1 | RIP1K INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584758-B2 | RIP1K inhibitors | RIPK1, RIPK2, RIPK3 | SYK 1934/4885MBOAT4 3407/4885CTSK 876/4885 |
| US-12043629-B2 | RIP1K inhibitors | RIPK1, RIPK2, RIPK3 | SYK 1934/4885MBOAT4 3407/4885CTSK 876/4885 |
| US-20230227469-A1 | RIP1K INHIBITORS | RIPK1, RIPK2, RIPK3 | SYK 1934/4885MBOAT4 3407/4885CTSK 876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.